Patent · US Active

Crystal form A of 7-(cyclopropylmethyl)-1-(((cis )-4-hydroxy-4-methylcyclohexyl)methyl)-3-methyl-1H-purine-2,6-(3H,7H)-dione for treating liver diseases

US10399981B2 · kind B2 · utility

1Cited by

1References

17Claims

0Family size

Assignee

GUANGDONG RAYNOVENT BIOTECH CO., LTD. · CN

Inventors

Lingyun WU · Shanghai, CN
Chaofeng Long · Tangxia, CN
Peng Zhang · Nanhu, CN
Xiaoxin Chen · Cupertino, US
Li Zhang · New Milford, US
Zhuowei Liu · 流花街道, CN
Zheng Wang · 安丰镇, CN
Shuhui CHEN · Shanghai, CN
Lijuan Chen · Dongguan, CN

Key dates

Filing date	Oct 27, 2016
Grant date	Sep 3, 2019
Priority date	—
Expiry date	Oct 27, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention discloses a crystal form A of a compound (I) and a preparation method thereof, and further discloses an application of the crystal form A as a PDE2 or TNF-α inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.